Saturday 17 October 2026
Export ASBP’s income statement to Excel — free account
Aspire-Lakewood Holdings, Inc.
ASBP Healthcare Biotechnology
Aspire-Lakewood Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,200.00. In the quarter to June 2026, EPS grew 97.5%, free cash flow fell 85.5% and total debt fell 79.7%, each against the same quarter a year earlier.
8.78
0.14
+1.62%
Follow ASBP
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 |
Altman Z-Score |
— | — | — | — | (83.47) |
P/S ratio |
— | — | — | — | 0.00 |
P/FCF ratio |
— | — | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | (199.09) |
P/Operating CF |
— | — | — | — | (0.28) |
P/B ratio |
— | — | — | — | 0.00 |
Price to Tangible BV |
— | — | — | — | 0.00 |
EV/Sales |
— | — | — | — | 0.00 |
EV/EBITDA |
— | — | — | — | 0.00 |
EV/Operating CF |
— | — | — | — | (0.42) |
EV/FCF |
— | — | — | — | (0.42) |
Quick Ratio |
0.00 | 1.64 | 0.00 | 0.00 | 0.13 |
Current Ratio |
1.00 | 3.62 | 0.20 | 0.09 | 0.17 |
Net Debt/EBITDA |
(9.36) | 0.51 | 0.00 | (11.36) | (0.16) |
Debt/Assets |
81.38% | 0.00% | 0.00% | 9,297.84% | 212.66% |
Debt/Equity |
(477.20) | 0.00 | 0.00 | (8.93) | (0.44) |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.01 |
Operating CF/Net income |
9.36 | (0.42) | (0.15) | 0.20 | 0.20 |
Capex/Depreciation |
— | — | — | — | 0.00 |
Interest Coverage |
— | (0.23) | (148.91) | (12.36) | (2.27) |
| 0.00% | (67.22%) | (87.02%) | 140.68% | 618.49% | |
| 0.00% | 2.22% | 2.79% | (13.01%) | (3,353.09%) | |
ROIC |
(6.69%) | 0.00% | 0.00% | (6.19%) | 0.00% |
Return on Tangible Assets |
5,100.00% | 420.42% | (1,385.94%) | 85.05% | 389.79% |
Average Days of Receivables |
— | — | — | — | 0.00 |
Research and Development Expense of Revenue |
— | — | — | 0.00% | 14,901.61% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 297,214.52% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | — | 227,924.19% |
Graham Net Nets |
— | — | — | — | (24.25) |
Graham Number |
— | — | — | — | 1,193.46 |
Earnings Yield |
— | — | — | — | (9,363.89%) |
Free Cash Flow Yield |
— | — | — | — | (1,872.45%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.12 |
Operating CF per Share |
(45.88) | (234.80) | (283.96) | (11.53) | (98.87) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(45.88) | (234.80) | (283.96) | (11.53) | (98.87) |
Cash per Share |
0.00 | 82.88 | 0.00 | 0.16 | 20.16 |
Shareholders Equity per Share |
(0.10) | (1,656.32) | (140.04) | (66.96) | (128.04) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.10) | (1,656.32) | (140.04) | (66.96) | (128.04) |
Free Cash Flow |
(0.24) | (1.41) | (0.65) | (0.27) | (4.92) |
Working Capital |
0.00 | 0.79 | (0.32) | (1.54) | (6.28) |
Net Current Asset Value |
0.00 | (309.02) | (20.22) | (1.54) | (6.38) |
EV/EBIT |
— | — | — | — | 0.00 |
Capex to Sales |
— | — | — | — | 0.00 |
Price to Operating Income |
— | — | — | — | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
— | — | — | — | 0.00 |
Cash ROIC |
(100.21%) | 14.92% | 202.76% | (2.17%) | 190.69% |
Accounts Receivable Turnover |
— | — | — | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.01 |
Inventory Turnover |
— | — | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 58,770.79 |
Days of Inventory on Hand |
— | — | — | — | 14,669.52 |
Average Payables |
— | 0.09 | 0.17 | 0.23 | 0.66 |
Average Assets |
— | 150.24 | 160.08 | 10.07 | 0.73 |
Average Common Equity |
— | (4.97) | (5.13) | (0.93) | (3.96) |
Columns are period end dates